Showing results (681-690 of 705) with videos related to

Sort By:
Pageof 71
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2015
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group StudyPaul J Goodfellow, Caroline C Billingsley, Heather A Lankes, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Gynecologic Oncology|May 29, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialMatthew A Powell, Henrik Roed, Lyndsay J Willmott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
Plos One|December 6, 2024
Development of a novel methodology for ascertaining scientific opinion and extent of agreementPeter Vickers, Ludovica Adamo, Mark Alfano, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nucleic Acids Research|November 22, 2013
RefSeq: an update on mammalian reference sequencesKim D Pruitt, Garth R Brown, Susan M Hiatt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trialM A Powell, L Bjørge, L Willmott, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Pageof 71